IBI3014 is a bispecific ADC targeting TROP2 and PD-L1. Its dual mechanism integrates TROP2-directed tumor killing with PD-L1 ...

SAN FRANCISCO and SUZHOU, China, April 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN, Mass., ...

Attovia Therapeutics has completed an oversubscribed $90 million Series C financing, which the company plans to use along with existing cash and investments to advance its two lead pipeline candidates ...

Vera Therapeutics, Inc.’s VERA share price has surged by 6.17%, which has investors questioning if this is right time to sell.

Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -- KPL-387 ...

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 7.99%, which has investors questioning if this is right ...

RT-114 combines ProGen's FC fusion protein conjugated GLP ... 19 molecules now and several of them are larger proteins like monoclonal antibodies. And we've observed that it is a more efficient ...